Jafari Narjes, Nasehi Mohammad Mehdi, Nasiri Eghbali Aiden, Taghdiri Mohammad Mahdi, Karimzadeh Parvaneh
Pediatrics Neurology Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Child Neurol. 2023 Summer;17(3):121-131. doi: 10.22037/ijcn.v17i2.36175. Epub 2023 Jul 1.
Migraine is a common disorder in children, and its prophylaxis with minimal side effects is momentous. This study aimed to compare the efficacy of Pregabalin and Sodium Valproate in preventing migraine attacks.
MATERIAL & METHODS: Sixty-four children (aged 6-18) with migraines were recruited, as defined by Internation Headache Criteria (ICHD-III). They were randomly assigned to two groups: Sodium Valproate (n=32) and Pregabalin (n=32). The minimum dosage of drugs was prescribed in both groups. The patients were followed for four months. The parameters such as frequency, intensity, duration of migraine attacks, and the number of painkillers that the patients used monthly were recorded. The Spence Children's anxiety scale was also used to evaluate medications' effect on patients' anxiety levels.
Two medications were equally effective in reducing the intensity and duration of attacks. Additionally, their effect on reducing the anxiety level of patients was equal. There was a significant difference between the effect of drugs on the frequency of migraine attacks at the end of the first and fourth months and the number of painkillers used at the end of the fourth month. The frequency of attacks was decreased by more than 50% in twenty-eight patients (90%) of Pregabalin recipients and twenty-one patients (84%) of Sodium Valproate recipients.
Considering the better effect of Pregabalin in the reduction of frequency of migraine attacks and pain-reducing medications consumption, Pregabalin could be a proper substitute for Sodium Valproate for prophylactic migraine treatment in children.
偏头痛是儿童常见疾病，采用副作用最小的预防方法至关重要。本研究旨在比较普瑞巴林和丙戊酸钠预防偏头痛发作的疗效。
招募了64名年龄在6至18岁的偏头痛儿童，符合国际头痛标准（ICHD-III）。他们被随机分为两组：丙戊酸钠组（n = 32）和普瑞巴林组（n = 32）。两组均采用最低药物剂量。对患者进行了四个月的随访。记录偏头痛发作的频率、强度、持续时间以及患者每月使用止痛药的数量等参数。还使用斯彭斯儿童焦虑量表评估药物对患者焦虑水平的影响。
两种药物在减轻发作强度和持续时间方面同样有效。此外，它们在降低患者焦虑水平方面的效果相同。在第一个月和第四个月末，药物对偏头痛发作频率的影响以及在第四个月末使用止痛药的数量之间存在显著差异。在普瑞巴林组的28名患者（90%）和丙戊酸钠组的21名患者（84%）中，发作频率降低了50%以上。
考虑到普瑞巴林在降低偏头痛发作频率和减少止痛药使用方面效果更好，普瑞巴林可作为丙戊酸钠的合适替代品，用于儿童偏头痛的预防性治疗。
